B. Metzler seel. Sohn & Co’s Axsome Therapeutics AXSM Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.26M	Hold	9,241	–	–	0.02%	396
2026 Q1	$1.56M	Hold	9,241	–	–	0.01%	446
2025 Q4	$1.69M	Hold	9,241	–	–	0.01%	444
2025 Q3	$1.12M	Hold	9,241	–	–	0.01%	517
2025 Q2	$965K	Hold	9,241	–	–	0.01%	551
2025 Q1	$1.08M	Hold	9,241	–	–	0.01%	504
2024 Q4	$782K	Hold	9,241	–	–	0.01%	578
2024 Q3	$830K	Hold	9,241	–	–	0.01%	576
2024 Q2	$744K	Hold	9,241	–	–	0.01%	577
2024 Q1	$737K	Hold	9,241	–	–	0.01%	569
2023 Q4	$735K	Buy	9,241 +1,056	+13%	+$70.6K	0.01%	551
2023 Q3	$572K	Sell	8,185 -6,975	-46%	-$521K	0.01%	563
2023 Q2	$1.09M	Buy	15,160 +8,059	+113%	+$595K	0.01%	477
2023 Q1	$438K	Buy	7,101 +660	+10%	+$43.4K	0.01%	572
2022 Q4	$497K	Sell	6,441 -3,869	-38%	-$231K	0.01%	557
2022 Q3	$460K	Buy	10,310 +556	+6%	+$27.8K	0.01%	554
2022 Q2	$374K	Hold	9,754	–	–	0.01%	607
2022 Q1	$404K	Buy	+9,754	New	+$302K	0.01%	640

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

B. Metzler seel. Sohn & Co's AXSM Position: Q2 2026 in Review

B. Metzler seel. Sohn & Co held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 9,241 shares worth $2.26M. The position accounts for 0.02% of the portfolio, ranked #396.

B. Metzler seel. Sohn & Co first reported a position in AXSM in Q1 2022 and has held it in 18 quarters since. 241 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

B. Metzler seel. Sohn & Co held 9,241 shares of Axsome Therapeutics worth $2.26M as of Q2 2026.
B. Metzler seel. Sohn & Co left its Axsome Therapeutics share count unchanged in Q2 2026.
Axsome Therapeutics made up 0.02% of B. Metzler seel. Sohn & Co's portfolio in Q2 2026, its #396 holding.
B. Metzler seel. Sohn & Co first reported a position in Axsome Therapeutics in Q1 2022 and has held it in 18 quarters since.
241 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q2 2026, filed 11 Aug 2026.